Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
This third tranche of funding within the BARDA OTA will support our two ongoing phase 3 studies with fosmanogepix in…
BEAM at work
Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.
